Treatment of XXXX .

@entity1 @entity8 @entity2361 @entity2631 @entity2407 @entity4770 @entity205 @entity379 @entity401 @entity2553 @entity785
Although there have been no major breakthroughs in @entity2631 therapy, new treatments have been tested in @entity1 with @entity785 , including both interferon alfa and @entity379 . These biologic agents can reduce collagen synthesis, which is a rational target for @entity2631 therapy. Debate about the use of photopheresis continues, and it was suggested in a recent editorial that photopheresis is no better than @entity2361 in the treatment of @entity2631 and is more expensive. @entity205 appears to have frequent @entity8 when used to treat @entity2631 . Outcome measurements have been concentrated on in @entity2631 trials. Several types of @entity2631 classifications were compared, and the classification of diffuse and limited @entity2631 was strongly related to disease severity. Skin score was systematically compared with mapping the surface area of involved skin, and the skin score was found to be more reliable. A possible prognostic indicator in @entity2631 is high-resolution pulmonary computed tomography, which is sensitive in early detection of @entity2631 -associated @entity401 . Classification of @entity2407 into primary and secondary forms has been proposed, and further testing of the criteria and long-term follow-up is necessary to validate this classification. Over the past year, treatment of @entity2553 with @entity4770 analogues has been efficacious with iloprost but not with low-dose oral cicaprost. Tissue plasminogen activator is not beneficial in the treatment of @entity2407 . A report of radical microarteriolysis for the treatment of refractory @entity2407 seems promising, warranting further investigation.
